[Results of percutaneous cryoablation for malignant lung tumors compared with radiotherapy]

Yoshikane Yamauchi, Masafumi Kawamura, Masanori Inoue, Hideki Yashiro, Seishi Nakatsuka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Radiotherapy has been regularly applied mainly for inoperable patients with non- small cell lung cancer, and various clinical trials have been performed. On the other hand, we have applied percutaneous cryoablation for lung tumors (PCLT) since 2002. In this paper, we describe our experience of PCLT compared to the results of radiation treatment. Three-year local progression-free rates with stereotactic body radiotherapy were 79-92% in stage I A and 30-79% in stage I B. Those with proton radiotherapy were 82-89% in stage I A and 49-62% in stage I B. CTCAE grade ≥3 complications occurred in 3-28% cases, such as radiation pneumonitis. As for PCLT, 1-, 2- and 3-year local progression-free rates were 80.4%, 69.0% and 67.7%, respectively. Pneumothorax, pleural effusion, and hemoptysis occurred after 61.7%, 70.5%, and 36.8% sessions, respectively. Of all cases with pneumothorax, 17.6% required chest tube insertion and 1.7% required pleurodesis. Delayed and recurrent pneumothorax occurred in 7.8% each. CTCAE grade ≥3 complications occurred in 1.5% cases. The biggest advantage of PCLT compared with radiotherapy is the possibility to treat local recurrence at the same site as treated before. In addition, no radiation pneumonitis occurs in PCLT. Moreover, less space or budget is needed when PCLT is newly introduced in a hospital. Although high reliable clinical data is not achieved yet, PCLT is one of the promising methods in local treatment.

Original languageEnglish
Pages (from-to)747-752
Number of pages6
JournalKyobu geka. The Japanese journal of thoracic surgery
Volume67
Issue number8
Publication statusPublished - 2014 Jul 1

Fingerprint

Cryosurgery
Radiotherapy
Lung
Pneumothorax
Neoplasms
Radiation Pneumonitis
Pleurodesis
Chest Tubes
Hemoptysis
Radiosurgery
Budgets
Pleural Effusion
Non-Small Cell Lung Carcinoma
Protons
Clinical Trials
Radiation
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Results of percutaneous cryoablation for malignant lung tumors compared with radiotherapy]. / Yamauchi, Yoshikane; Kawamura, Masafumi; Inoue, Masanori; Yashiro, Hideki; Nakatsuka, Seishi.

In: Kyobu geka. The Japanese journal of thoracic surgery, Vol. 67, No. 8, 01.07.2014, p. 747-752.

Research output: Contribution to journalArticle

@article{bd3eae97981a49f8a77f0d9d71f82dc6,
title = "[Results of percutaneous cryoablation for malignant lung tumors compared with radiotherapy]",
abstract = "Radiotherapy has been regularly applied mainly for inoperable patients with non- small cell lung cancer, and various clinical trials have been performed. On the other hand, we have applied percutaneous cryoablation for lung tumors (PCLT) since 2002. In this paper, we describe our experience of PCLT compared to the results of radiation treatment. Three-year local progression-free rates with stereotactic body radiotherapy were 79-92{\%} in stage I A and 30-79{\%} in stage I B. Those with proton radiotherapy were 82-89{\%} in stage I A and 49-62{\%} in stage I B. CTCAE grade ≥3 complications occurred in 3-28{\%} cases, such as radiation pneumonitis. As for PCLT, 1-, 2- and 3-year local progression-free rates were 80.4{\%}, 69.0{\%} and 67.7{\%}, respectively. Pneumothorax, pleural effusion, and hemoptysis occurred after 61.7{\%}, 70.5{\%}, and 36.8{\%} sessions, respectively. Of all cases with pneumothorax, 17.6{\%} required chest tube insertion and 1.7{\%} required pleurodesis. Delayed and recurrent pneumothorax occurred in 7.8{\%} each. CTCAE grade ≥3 complications occurred in 1.5{\%} cases. The biggest advantage of PCLT compared with radiotherapy is the possibility to treat local recurrence at the same site as treated before. In addition, no radiation pneumonitis occurs in PCLT. Moreover, less space or budget is needed when PCLT is newly introduced in a hospital. Although high reliable clinical data is not achieved yet, PCLT is one of the promising methods in local treatment.",
author = "Yoshikane Yamauchi and Masafumi Kawamura and Masanori Inoue and Hideki Yashiro and Seishi Nakatsuka",
year = "2014",
month = "7",
day = "1",
language = "English",
volume = "67",
pages = "747--752",
journal = "Japanese Journal of Thoracic Surgery",
issn = "0021-5252",
publisher = "Nankodo Co., Ltd.",
number = "8",

}

TY - JOUR

T1 - [Results of percutaneous cryoablation for malignant lung tumors compared with radiotherapy]

AU - Yamauchi, Yoshikane

AU - Kawamura, Masafumi

AU - Inoue, Masanori

AU - Yashiro, Hideki

AU - Nakatsuka, Seishi

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Radiotherapy has been regularly applied mainly for inoperable patients with non- small cell lung cancer, and various clinical trials have been performed. On the other hand, we have applied percutaneous cryoablation for lung tumors (PCLT) since 2002. In this paper, we describe our experience of PCLT compared to the results of radiation treatment. Three-year local progression-free rates with stereotactic body radiotherapy were 79-92% in stage I A and 30-79% in stage I B. Those with proton radiotherapy were 82-89% in stage I A and 49-62% in stage I B. CTCAE grade ≥3 complications occurred in 3-28% cases, such as radiation pneumonitis. As for PCLT, 1-, 2- and 3-year local progression-free rates were 80.4%, 69.0% and 67.7%, respectively. Pneumothorax, pleural effusion, and hemoptysis occurred after 61.7%, 70.5%, and 36.8% sessions, respectively. Of all cases with pneumothorax, 17.6% required chest tube insertion and 1.7% required pleurodesis. Delayed and recurrent pneumothorax occurred in 7.8% each. CTCAE grade ≥3 complications occurred in 1.5% cases. The biggest advantage of PCLT compared with radiotherapy is the possibility to treat local recurrence at the same site as treated before. In addition, no radiation pneumonitis occurs in PCLT. Moreover, less space or budget is needed when PCLT is newly introduced in a hospital. Although high reliable clinical data is not achieved yet, PCLT is one of the promising methods in local treatment.

AB - Radiotherapy has been regularly applied mainly for inoperable patients with non- small cell lung cancer, and various clinical trials have been performed. On the other hand, we have applied percutaneous cryoablation for lung tumors (PCLT) since 2002. In this paper, we describe our experience of PCLT compared to the results of radiation treatment. Three-year local progression-free rates with stereotactic body radiotherapy were 79-92% in stage I A and 30-79% in stage I B. Those with proton radiotherapy were 82-89% in stage I A and 49-62% in stage I B. CTCAE grade ≥3 complications occurred in 3-28% cases, such as radiation pneumonitis. As for PCLT, 1-, 2- and 3-year local progression-free rates were 80.4%, 69.0% and 67.7%, respectively. Pneumothorax, pleural effusion, and hemoptysis occurred after 61.7%, 70.5%, and 36.8% sessions, respectively. Of all cases with pneumothorax, 17.6% required chest tube insertion and 1.7% required pleurodesis. Delayed and recurrent pneumothorax occurred in 7.8% each. CTCAE grade ≥3 complications occurred in 1.5% cases. The biggest advantage of PCLT compared with radiotherapy is the possibility to treat local recurrence at the same site as treated before. In addition, no radiation pneumonitis occurs in PCLT. Moreover, less space or budget is needed when PCLT is newly introduced in a hospital. Although high reliable clinical data is not achieved yet, PCLT is one of the promising methods in local treatment.

UR - http://www.scopus.com/inward/record.url?scp=84925222247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925222247&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 747

EP - 752

JO - Japanese Journal of Thoracic Surgery

JF - Japanese Journal of Thoracic Surgery

SN - 0021-5252

IS - 8

ER -